YB-101 / GeneScience, Yarrow Bioscience - LARVOL DELTA

Yarrow Bioscience maps YB-101, $200M funding (StockTitan.net) - "Yarrow details a global license from GenSci, including a $70 million upfront payment, up to $1.295 billion in milestones, and tiered royalties in the low to low‑mid teens on ex‑China sales. The company reports $200 million raised to date and states its cash runway is expected to fund operations into 2028."

Financing • Grave’s Disease • Thyroid Eye Disease

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease (Businesswire) - "The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED, and the molecule has received Fast Track Designation from the U.S. Food and Drug Administration ('FDA'). Data from the Phase 2a portion of the trial are expected in the second half of 2027....Data from the MAD portion of GenSci’s Phase 1 TED trial are anticipated in the second half of 2027 and will inform future development plans for YB-101 in TED globally."

Fast track • M&A • P1 data • P2a data • Trial status • Grave’s Disease • Thyroid Eye Disease

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease (clinicaltrials.gov) - P2 | N=232 | Recruiting | Sponsor: Yarrow Bioscience, Inc.

New P2 trial • Endocrine Disorders • Grave’s Disease

Alpibectir-Ethionamide combination (AlpE) for the treatment of tuberculosis. (PubMed, Nat Commun) - "Through biophysical, genetic, and cellular assays, we show that the clinical candidate alpibectir (Alp, BVL-GSK098) binds the transcriptional regulator VirS, increasing MymA expression and potentiating Eto and Pto activity. Alpibectir was safe in a Phase 1 human clinical trial. Together with the potentiation data presented here, these findings highlight its potential to optimize TB chemotherapy by reducing Eto/Pto doses, which can minimize dose-related side effects, enhancing adherence."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

GenSci098-102: A Study of GensSci098 in Subjects With Graves' Disease (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Endocrine Disorders • Grave’s Disease